AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28341722 — intervention group
Group type: EXPERIMENTAL
Intervention: BUPI (bupivacaine 0.46%, 0.46 mg/kg)
Number of subjects: 6
Study 28341722 — intervention group
Group type: EXPERIMENTAL
Intervention: BUPI-DEX (bupivacaine with dexmedetomidine 1 µg/kg)
Number of subjects: 6
Study 28341722 — intervention group
Group type: EXPERIMENTAL
Intervention: BUPI-BUPRE (bupivacaine with buprenorphine 2.5 µg/kg)
Number of subjects: 6
Study 28341722 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (saline)
Number of subjects: 6
Study 28341722 — intervention group
Group type: EXPERIMENTAL
Intervention: BUPI
Number of subjects: 6
Study 28341722 — intervention group
Group type: EXPERIMENTAL
Intervention: BUPI-DEX
Number of subjects: 6
Study 28341722 — intervention group
Group type: EXPERIMENTAL
Intervention: BUPI-BUPRE
Number of subjects: 6
Study 25442243 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid 2000/125 mg
Number of subjects: 118
Study 25442243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 24135322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib (RO4607381)
Number of subjects: 130
Study 21768544 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d ezetimibe + 2.5 g phytosterols
Number of subjects: 21
Study 21768544 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d ezetimibe + phytosterol placebo
Number of subjects: 21
Study 21768544 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe placebo + phytosterol placebo
Number of subjects: 21
Study 19451666 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Greek traditional dance classes for 10 weeks (1 hr, 2 sessions/week, n = 14)
Number of subjects: 26
Study 19451666 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 26
Study 16403107 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate
Number of subjects: 40
Study 16403107 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin
Number of subjects: 40
Study 14716792 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight composite multifilament mesh (polypropylene 27‐30 g/m(2))
Number of subjects: 122
Study 14716792 — intervention group
Group type: COMPARATOR
Intervention: Conventional densely woven polypropylene mesh (100‐110 g/m(2))
Number of subjects: 122
Study 14716792 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 122
Study 11385124 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic wardens (outdoor workers)
Number of subjects: 99
Study 11385124 — intervention group
Group type: COMPARATOR
Intervention: Office workers
Number of subjects: 99
Study 11385124 — intervention group
Group type: COMPARATOR
Intervention: Environmental monitoring
Number of subjects: 99
Study 11385124 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood benzene
Number of subjects: 99
Study 11385124 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hydroxypyrene and trans-muconic acid excretion
Number of subjects: 99
Study 9028693 — intervention group
Group type: COMPARATOR
Intervention: Standard 16‐week group behavioral weight‐control program
Number of subjects: 22
Study 9028693 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 16‐week group behavioral weight‐control program with three individualized motivational interviewing sessions
Number of subjects: 22
Study 8398224 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic interventions (specific interventions not detailed in the abstract)
Number of subjects: 2182
Study 8398224 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mailings and work site screenings (strategies for recruitment)
Number of subjects: 2182
Study 8398224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort or wave type of enrollment
Number of subjects: 2182
Study 3780685 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 182
Study 3780685 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride 100 mg
Number of subjects: 182
Study 3780685 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride 200 mg
Number of subjects: 182
Study 3780685 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 182
Study 3780685 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 182
Study 31900543 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg)
Number of subjects: 53
Study 31900543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 29383894 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity TEAS (10 mA)
Number of subjects: 150
Study 29383894 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity TEAS (5 mA)
Number of subjects: 150
Study 29383894 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mA)
Number of subjects: 150
Study 26725257 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM patients
Number of subjects: 30
Study 26725257 — intervention group
Group type: COMPARATOR
Intervention: Control group (NC)
Number of subjects: 30
Study 25366037 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 20
Study 25366037 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (5 to 10 mg twice daily)
Number of subjects: 20
Study 22504188 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL/THD procedure without Doppler transducer (non-Doppler group)
Number of subjects: 82
Study 22504188 — intervention group
Group type: COMPARATOR
Intervention: Conventional HAL/THD procedure (Doppler group)
Number of subjects: 82
Study 19935091 — intervention group
Group type: EXPERIMENTAL
Intervention: c‐pharm early (sertraline at 150 mg/d)
Number of subjects: 0
Study 19935091 — intervention group
Group type: EXPERIMENTAL
Intervention: c‐pharm late (placebo initially, then sertraline at 150 mg/d)
Number of subjects: 0
Study 19935091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18035205 — intervention group
Group type: EXPERIMENTAL
Intervention: THC/CBD oromucosal spray (27 mg/mL: 25 mg/mL)
Number of subjects: 66
Study 18035205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 16198887 — intervention group
Group type: EXPERIMENTAL
Intervention: LBBB group (n = 40) with LVEF < 50%
Number of subjects: 89
Study 16198887 — intervention group
Group type: EXPERIMENTAL
Intervention: LBBB group (n = 40) with LVEF >= 50%
Number of subjects: 89
Study 16198887 — intervention group
Group type: EXPERIMENTAL
Intervention: LBBB group (n = 40)
Number of subjects: 89
Study 16198887 — intervention group
Group type: COMPARATOR
Intervention: RV pacing group (n = 26)
Number of subjects: 89
Study 16198887 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 23)
Number of subjects: 89
Study 12242979 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric pacing
Number of subjects: 0
Study 10419245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen to prevent recurrent febrile seizures
Number of subjects: 230
Study 7477928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal tilts (frequency 0.007 Hz, amplitude 1.5 degrees)
Number of subjects: 0
Study 7477928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp tilts (amplitude 1.0 and 0.25 degrees, angular velocity 0.04 degrees/s)
Number of subjects: 0
Study 2405131 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25‐dihydroxyvitamin D
Number of subjects: 108
Study 2405131 — intervention group
Group type: COMPARATOR
Intervention: dihydrotachysterol
Number of subjects: 108
Study 6932833 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 5 mg
Number of subjects: 11
Study 6932833 — intervention group
Group type: COMPARATOR
Intervention: Prazosin therapy (4 weeks)
Number of subjects: 11
Study 31558478 — intervention group
Group type: EXPERIMENTAL
Intervention: MET141 low-risk subgroup (lowest 25th percentile of scores)
Number of subjects: 454
Study 31558478 — intervention group
Group type: EXPERIMENTAL
Intervention: MET141 low-risk patients in the METABRIC cohort
Number of subjects: 454
Study 29082755 — intervention group
Group type: EXPERIMENTAL
Intervention: compression stockings group
Number of subjects: 18
Study 29082755 — intervention group
Group type: EXPERIMENTAL
Intervention: full‐leg compression group
Number of subjects: 18
Study 29082755 — intervention group
Group type: EXPERIMENTAL
Intervention: shorts group
Number of subjects: 18
Study 29082755 — intervention group
Group type: COMPARATOR
Intervention: control (no compression garments)
Number of subjects: 18
Study 27382104 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP8
Number of subjects: 364
Study 27382104 — intervention group
Group type: COMPARATOR
Intervention: CHOP3RT
Number of subjects: 364
Study 27382104 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab + CHOP3RT (S0014)
Number of subjects: 364
Study 24777901 — intervention group
Group type: EXPERIMENTAL
Intervention: Resident Antimicrobial Management Plan (RAMP)
Number of subjects: 1628
Study 24777901 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RAMP)
Number of subjects: 1628
Study 22779383 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated milk (0.5 mgF per 189 ml carton)
Number of subjects: 50
Study 22779383 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated milk (0.9 mgF per 189 ml carton)
Number of subjects: 50
Study 22779383 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoridated milk
Number of subjects: 50
Study 19718394 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg daily)
Number of subjects: 112
Study 19718394 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (1 microg daily)
Number of subjects: 112
Study 17167264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (group A)
Number of subjects: 10
Study 17167264 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoride dentifrice (group B)
Number of subjects: 10
Study 15103313 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 4287
Study 15103313 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 4287
Study 12366499 — intervention group
Group type: EXPERIMENTAL
Intervention: Global haemostatic tests (INR and APTT)
Number of subjects: 184
Study 12366499 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged APTT
Number of subjects: 184
Study 12366499 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients not fulfilling laboratory criteria)
Number of subjects: 184
Study 10194484 — intervention group
Group type: EXPERIMENTAL
Intervention: Stripping of the long saphenous vein
Number of subjects: 100
Study 10194484 — intervention group
Group type: COMPARATOR
Intervention: Saphenofemoral ligation alone
Number of subjects: 100
Study 7790946 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (6 or 12 mg daily)
Number of subjects: 15
Study 7790946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2134443 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (MP)
Number of subjects: 43
Study 2134443 — intervention group
Group type: COMPARATOR
Intervention: Control group (without steroid drug)
Number of subjects: 43
Study 340326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1200 mg per day for 6 weeks)
Number of subjects: 85
Study 340326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 340326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 85
Study 30573503 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab-based immunochemotherapy
Number of subjects: 1202
Study 30573503 — intervention group
Group type: COMPARATOR
Intervention: Rituximab-based immunochemotherapy
Number of subjects: 1202
Study 30573503 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 1202
Study 27642816 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline cortical bone trajectory (CBT) pedicle screws in outpatient surgery center (OSC)
Number of subjects: 60
Study 27642816 — intervention group
Group type: COMPARATOR
Intervention: Traditional pedicle screws in hospital
Number of subjects: 60
Study 25842271 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Number of subjects: 987
Study 25842271 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (in-clinic visits)
Number of subjects: 987
Study 25842271 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring among CRT-D recipients
Number of subjects: 987
Study 25842271 — intervention group
Group type: COMPARATOR
Intervention: Standard arm among CRT-D recipients
Number of subjects: 987
Study 25842271 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring among ICD patients
Number of subjects: 987
Study 25842271 — intervention group
Group type: COMPARATOR
Intervention: Standard arm among ICD patients
Number of subjects: 987
Study 24088689 — intervention group
Group type: EXPERIMENTAL
Intervention: Family planning educational intervention videos
Number of subjects: 0
Study 24088689 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive family planning services
Number of subjects: 0
Study 21059626 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 3g/day
Number of subjects: 96
Study 21059626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 19016720 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim therapy
Number of subjects: 0
Study 19016720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17996996 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-MenCY-TT co-administered with DTPa-HBV-IPV and PCV7
Number of subjects: 0
Study 15249851 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured intervention
Number of subjects: 39
Study 15249851 — intervention group
Group type: COMPARATOR
Intervention: Counseling AI (control group)
Number of subjects: 39
Study 14749690 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 8 mg daily
Number of subjects: 200
Study 14749690 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 16 mg daily
Number of subjects: 200
Study 14749690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 10077717 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis and self-hypnosis administered and taught by nurses
Number of subjects: 0
Study 10077717 — intervention group
Group type: COMPARATOR
Intervention: Control group (instrumental and pharmacological management of chronic pain)
Number of subjects: 0
Study 7719273 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective digestive decontamination (SDD)
Number of subjects: 0
Study 7719273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2038044 — intervention group
Group type: EXPERIMENTAL
Intervention: Appraisal of Diabetes Scale (ADS)
Number of subjects: 200
Study 2038044 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional measures of diabetes-related health beliefs, diabetic daily hassles, perceived stress, diabetic adherence, and psychiatric symptoms
Number of subjects: 200
Study 2038044 — intervention group
Group type: EXPERIMENTAL
Intervention: ADS on two additional occasions
Number of subjects: 200
Study 7196467 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 0
Study 7196467 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term antihypertensive treatment
Number of subjects: 0
Study 7196467 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure at home
Number of subjects: 0
Study 31888706 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 800
Study 31888706 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 800
Study 28402128 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletally anchored Class II elastics
Number of subjects: 12
Study 28402128 — intervention group
Group type: COMPARATOR
Intervention: Monobloc appliance
Number of subjects: 12
Study 26404990 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-assisted learning (PAL) by BDS5 peer tutors
Number of subjects: 2
Study 26404990 — intervention group
Group type: COMPARATOR
Intervention: Staff-led groups
Number of subjects: 2
Study 24215306 — intervention group
Group type: EXPERIMENTAL
Intervention: Community screening and treatment of asymptomatic carriers of P. falciparum
Number of subjects: 13767
Study 24215306 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 13767
Study 21415174 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-P tests
Number of subjects: 14
Study 19716683 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (up to 1.2 mg/kg/day)
Number of subjects: 139
Study 19716683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 19716683 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine and Placebo
Number of subjects: 139
Study 17355270 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version
Number of subjects: 805
Study 15274379 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative whole-liver chemolipiodolization
Number of subjects: 59
Study 15274379 — intervention group
Group type: COMPARATOR
Intervention: Preoperative selective chemolipiodolization
Number of subjects: 59
Study 11405286 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg risedronate as a tablet
Number of subjects: 33
Study 11405286 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg risedronate as an aqueous solution
Number of subjects: 33
Study 11405286 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg risedronate as an intravenous infusion
Number of subjects: 33
Study 11405286 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration
Number of subjects: 33
Study 9563277 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled diabetes in scleredema patients with diabetes (5 out of 11 patients showed improvement)
Number of subjects: 21
Study 9563277 — intervention group
Group type: COMPARATOR
Intervention: Scleredema without diabetes (8 out of 10 patients)
Number of subjects: 21
Study 9563277 — intervention group
Group type: COMPARATOR
Intervention: Facial involvement in scleredema patients without diabetes
Number of subjects: 21
Study 7812419 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equation group using computed tomography (CT) for adipose tissue areas at the L4-L5 level.
Number of subjects: 93
Study 7812419 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured adipose tissue areas by CT.
Number of subjects: 93
Study 7812419 — intervention group
Group type: EXPERIMENTAL
Intervention: Single best predictors of measured adipose tissue areas.
Number of subjects: 93
Study 7812419 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple and safe anthropometric measurements.
Number of subjects: 93
Study 29133948 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-depressant medications (ADMs): escitalopram, sertraline, or venlafaxine-extended release for 8 weeks
Number of subjects: 202
Study 29133948 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 202
Study 27863515 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+), delivered by community health workers, n = 35
Number of subjects: 70
Study 27863515 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU), n = 35
Number of subjects: 70
Study 25337750 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 508
Study 25337750 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 508
Study 23778061 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education interventions targeting specific populations among Ahmedabad urban slum dwellers
Number of subjects: 0
Study 23778061 — intervention group
Group type: COMPARATOR
Intervention: Heat exposure and vulnerability factors
Number of subjects: 0
Study 20177974 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (BPN/NLX)
Number of subjects: 69
Study 18547268 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated headache management program (class on headache types, triggers, treatment options; diagnosis and treatment by trained professional; proactive follow-up by case manager) for 6 months
Number of subjects: 0
Study 18547268 — intervention group
Group type: COMPARATOR
Intervention: Usual care from primary care providers
Number of subjects: 0
Study 18547268 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated headache management program
Number of subjects: 0
Study 16988115 — intervention group
Group type: EXPERIMENTAL
Intervention: PSY+PS cookie (7.68 g/d PSY and 2.6 g/d PS)
Number of subjects: 33
Study 14574660 — intervention group
Group type: EXPERIMENTAL
Intervention: BUN >= 15 mg/dL (sensitive cutpoint)
Number of subjects: 7000
Study 14574660 — intervention group
Group type: EXPERIMENTAL
Intervention: BUN >= 20 mg/dL (high-yield cutpoint)
Number of subjects: 7000
Study 10937315 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in automation
Number of subjects: 0
Study 10937315 — intervention group
Group type: COMPARATOR
Intervention: Trust in human partners
Number of subjects: 0
Study 8957978 — intervention group
Group type: EXPERIMENTAL
Intervention: Midlatency auditory evoked potentials (MLAEP)
Number of subjects: 41
Study 8957978 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EEG, MLAEP, MAP and T measures
Number of subjects: 41
Study 1551309 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice (50 g carbohydrate) eaten as part of a mixed meal (32 g protein, 20 g fat)
Number of subjects: 30
Study 1551309 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (50 g carbohydrate) eaten as part of a mixed meal (32 g protein, 20 g fat)
Number of subjects: 30
Study 1551309 — intervention group
Group type: COMPARATOR
Intervention: Rice (50 g carbohydrate) eaten alone
Number of subjects: 30
Study 1551309 — intervention group
Group type: COMPARATOR
Intervention: Glucose (50 g carbohydrate) eaten alone
Number of subjects: 30
Study 4025172 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 9
Study 4025172 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 9
Study 4025172 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Propranolol + Hydralazine)
Number of subjects: 9
Study 4025172 — intervention group
Group type: COMPARATOR
Intervention: Diuretic-only therapy
Number of subjects: 9